Xie Yunhe, Ye Jiarong, Luo Hongliang
Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330008, People's Republic of China.
Department of General Surgery, Jiujiang Hospital of Traditional Chinese Medicine, Jiujiang, Jiangxi, 332007, People's Republic of China.
Onco Targets Ther. 2023 Oct 24;16:849-865. doi: 10.2147/OTT.S425523. eCollection 2023.
HOXC cluster antisense RNA 3 (HOXC-AS3) is a novel long noncoding RNA (lncRNA) that exhibits aberrant expression patterns in various cancer types. Its expression is closely related to clinicopathological features, demonstrating significant clinical relevance across multiple tumors. And HOXC-AS3 plays multifaceted roles in tumor progression, impacting cell proliferation, apoptosis, migration, invasion, epithelial-mesenchymal transition (EMT), autophagy, senescence, tumor growth, and metastasis. In this review, we summarized and comprehensively analyzed the expression and clinical significance of HOXC-AS3 as a diagnostic and prognostic biomarker for malignancies. Additionally, we presented an in-depth update on HOXC-AS3's functions and regulatory mechanisms in cancer pathogenesis. This narrative review underscores the importance of HOXC-AS3 as a promising lncRNA candidate in cancer research and its potential as a predictive biomarker and therapeutic target in clinical applications.
J Cancer Res Clin Oncol. 2024-6-6
Expert Rev Respir Med. 2022-5
In Vitro Cell Dev Biol Anim. 2020-1-10
Cancer Invest. 2019-12-4
Biochim Biophys Acta Rev Cancer. 2023-7
Cell Commun Signal. 2023-5-1
Semin Cancer Biol. 2023-7
Noncoding RNA Res. 2023-3-14
Nat Rev Mol Cell Biol. 2023-6